Annual revenue rose from KRW 1.78 trillion in 2022 to KRW 2.19 trillion in 2025, growing for three consecutive years from 2023 through 2025 at rates of 4.7%, 11.2% and 5.7%.
Operating profit went from KRW 36 billion in 2022 to KRW 56.8 billion in 2023 (up 57.5%), fell to KRW 54.9 billion in 2024 (down 3.3%), and recovered to KRW 104.4 billion in 2025 (up 90.2%).
The operating margin rose from 2.0% in 2022 to 3.1% in 2023, eased to 2.7% in 2024, and reached 4.8% in 2025, the highest of 2022–2025.
Profit attributable to controlling shareholders was smallest in 2024 at KRW 70.7 billion (down 48.1%) and largest in 2025 at KRW 194.1 billion (up 174.6%), while net profit including non-controlling interests was KRW 185.3 billion in 2025, a different figure.
At its March 2026 general meeting, the company cited a 9.8% cut in R&D spending, milestone inflows from the China launch and steady growth in its high-margin lipid-lowering drug as 2025 drivers.
Operating cash flow rebounded from KRW 54.6 billion in 2024 to KRW 106.2 billion in 2025, and the debt ratio was 36.3% at end-2025 with total equity of KRW 2.36 trillion and total liabilities of KRW 858.6 billion.
In Q1 2026, revenue was KRW 526.8 billion and operating profit was KRW 8.82 billion, down 66.2% from the prior quarter, a drop that analysts in May 2026 linked to the European milestone moving into Q2.
Q2 2026 revenue of KRW 639.5 billion and operating profit of KRW 66.9 billion reflected that milestone, and a July 2026 report called them record quarterly levels.
Q3 2026 revenue was KRW 604.3 billion (up 6.0% year on year) and operating profit was KRW 33.2 billion (up 50.8%), yet profit attributable to controlling shareholders fell 18.3% to KRW 20.6 billion. About 40% of total milestones is paid to Oscotec and Genosco as R&D fees, so inflows do not fully translate into profit. Profit attributable to controlling shareholders over the last four quarters totaled KRW 232.4 billion.